key: cord-0894109-jvrzxwcx authors: Ardahanli, Isa; Akhan, Onur; Sahin, Ebru; Akgun, Onur; Gurbanov, Rafig title: Myocardial performance index increases at long‐term follow‐up in patients with mild to moderate COVID‐19 date: 2022-03-16 journal: Echocardiography DOI: 10.1111/echo.15340 sha: 8396d87d2ccb1d4fe6a7469bf1342ee1df9bb1e0 doc_id: 894109 cord_uid: jvrzxwcx BACKGROUND: The long‐term cardiovascular effects of Coronavirus disease‐2019 (COVID‐19) are not yet well known. Myocardial performance index (MPI) is a non‐invasive, inexpensive and reproducible echocardiographic parameter that reflects systolic and diastolic cardiac functions. The aim of the study was to compare MPI with a healthy control group in patients with mild or moderate COVID‐19 infection who subsequently had unexplained cardiac symptoms. METHODS: The study included 200 patients aged 18–70 years who were diagnosed with COVID‐19 infection at least 2 months ago and defined cardiac symptoms in their follow‐up. Patients with mild or moderate symptoms, no history of hospitalization, and no other pathology that could explain cardiac symptoms were included in the study. As the control group, 182 healthy volunteers without COVID‐19 were evaluated. Echocardiographic examination was performed on the entire study group. Isovolumetric contraction time (IVCT), isovolumetric relaxation time (IVRT), and ejection time (ET) were measured by tissue Doppler imaging. MPI was calculated with the IVCT+IVRT/ET formula. RESULTS: The mean age of the study group was 44.24 ± 13.49 years. In the patient group the MPI was significantly higher (.50 ± .11 vs .46 ± .07, p < .001), IVRT was longer (69.67 ± 15.43 vs 65.94 ± 12.03 ms, p = . 008), and ET was shorter (271.09 ± 36.61 vs 271.09 ± 36.61 ms, p = .028). IVCT was similar between groups (63.87 ± 13.66 vs. 63.21 ± 10.77 ms, p = .66). Mitral E and mitral A wave, E’, A’, and E/A were similar in both groups. CONCLUSIONS: Our study showed that conventional diastolic function parameters were not affected in patients who survived COVID‐19 with mild symptoms but had symptoms in the long term. However, MPI measurements showed left ventricular dysfunction. To our knowledge, this is the first echocardiographic follow‐up study to evaluate left ventricular systolic and diastolic functions with MPI in COVID‐19 patients. We think that when cardiac involvement assessment is required in patients who have survived COVID‐19, MPI should be measured alongside other echocardiographic measurements. COVID-19 pneumonia, reported in the Wuhan region of China in the last months of 2019, spread rapidly and turned into a pandemic that caused the death of 5.4 million people worldwide. 1, 2 The most common symptoms of the disease are respiratory system-related symptoms such as shortness of breath and cough. 3 Therefore, most of the previous studies focused on damage to the respiratory system. [4] [5] [6] However, it was soon seen that COVID-19 infection is a disease that can show widespread systematic involvement and is accompanied by multiorgan pathologies. 7, 8 Another important organ involvement is heart involvement like myocarditis, acute coronary syndrome, cardiomyopathy, and arrhythmias. [9] [10] [11] The main parameters used to determine heart damage caused by COVID-19 in clinical practice are electrocardiography (ECG), increased serum ischemia biomarkers, and ventricular dysfunction in transthoracic echocardiography. [12] [13] [14] Myocardial performance index (MPI) is a useful predictor of global myocardial performance, which provides the opportunity to evaluate both systolic and diastolic functions of the heart. 15 MPI, which was first defined by Tei et al., is also known as the Tei index. 16 This index is obtained by the echocardiographic tissue Doppler method. It is calculated by dividing the sum of isovolumetric contraction time (IVCT) and isovolumetric relaxation time (IVRT) by ejection time (ET) (MPI = IVCT+IVRT/ET). The fact that it is not affected by the geometric structure of the ventricle and is relatively unaffected by the heart rate is an important advantage compared to other classical echocardiographic parameters. 17 In the literature, there are many studies with conventional echocardiographic parameters in the investigation of cardiac dysfunction in COVID-19 patients. In most of these studies, patients in the active disease who had an asymptomatic course and had a general condition disorder, and needed intensive care were investigated. 18 In addition, the pathophysiological process is not yet clear in patient groups whose cardiac symptoms persist in the long term after infection and no pathology is detected in classical cardiac diagnostic methods. Our current study aim is to compare MPI with a healthy control group in patients with mild or moderate COVID-19 infection who have unexplained cardiac symptoms in the later period. The study was designed as a single-center cross-sectional and prospective. We enrolled patients aged 18- Surface ECGs were taken and laboratory analyzes were performed. All participants were informed about the study and their written consent was obtained. The approval of the Turkish Ministry of Health was obtained for the study and the approval of the local ethics committee was obtained. • Those with a history of hospitalization or intensive care series due to COVID-19. • Those with similar cardiac symptoms before the infection. • History of the acute coronary syndrome after COVID-19 infection. • Those with pulmonary sequelae due to COVID-19 infection on computerized tomography (CT). • Those with inadequate respiratory function tests. • Heart failure with reduced ejection fraction (LVEF ≤ 40%), and heart failure with mid-range ejection fraction (LVEF between 41% and 49%) • Those who have rapid weight gain after COVID-19 (as it can cause exertional dyspnea). • History of previous pulmonary embolism. • Active infection. • Pregnancy. • Presence of pathological Q wave or left bundle branch block on ECG. • Moderate and severe heart valve disease. • Severe anemia (Hg <11 gr/dl). • Endocrine disorders (thyroid dysfunction, diabetes mellitus type I and type II). • Pulmonary hypertension (SPAB > 20 mm-Hg). • Poor echogenicity and poor image quality. (Figure 1 ). The statistical analyses were given as mean ± standard deviation (SD). Unpaired T-test (one-sided p-value) was utilized to check the cardiac echocardiographic parameters of the COVID-19 patient (1) group against the healthy (2) group. The Kolmogorov-Smirnov test was used to analyze the normality of the data. All statistical tests were conducted using the Statistical Package for the Social Sciences 21.0 for Windows (SPSS Inc., Chicago, IL, USA). p < .05 was accepted as statistical significance. The mean age in the study group was 44.24 ± 13.49 years. There was no statistically significant age difference between the groups. In conven- In a recent study, cardiac performance was followed for 6 months in hospitalized patients with COVID-19, and evidence of myocardial injury, and diastolic dysfunction was reported to be common. However, they reported that diastolic dysfunction was not affected in the 6month follow-up of COVID-19 patients without cardiac involvement. 26 The difference in our study was that our patient group was not fol- 29 In this method, important information about the systolic and diastolic functions of the heart is obtained. However, it is not a method that can be performed in every cardiology clinic and its application requires experience. Another important finding in our study was that TAPSE, which is an indicator of right ventricular functions, was found to be significantly lower in the group who had the disease. This was consistent with other studies in the literature. 30 Unlike these studies, the patients in our study were not in the active infection period. TAPSE is a reliable, easily applicable, and reproducible method for determining right ventricular functions. 31 As a result, we determined that MPI, which allows the evaluation of both systolic and diastolic functions of the heart, is prolonged in patients who have had the disease but whose cardiac symptoms have persisted for a long time. MPI can be easily calculated by echocardiography and can provide information in patients with COVID-19 infection but with unexplained symptoms, which may help guide the management of this patient group. First, data were obtained from a single center. Second, while investigating the presence of cardiac involvement in patients, coronary angiography was not performed in all patients. In patients with suspected coronary ischemia, it was investigated whether there was ischemia by exercise test or myocardial perfusion scintigraphy. As is known, these tests are not standard diagnostic methods like coronary angiography in the diagnosis of coronary artery disease. There is no conflict of interest to be declared. No financial support was received from any person or institution in the study. Isa Ardahanli MD https://orcid.org/0000-0002-9309-803X Onur Akhan MD https://orcid.org/0000-0003-4440-9599 SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis WHO (2020) Coronavirus disease 2019 (COVID-19) Situation report -184 2020. World Health Organization Accessed Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19 Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Static compliance of the respiratory system in COVID-19 related ARDS: an international multicenter study The coagulopathy, endotheliopathy, and vasculitis of COVID-19 The case of complement activation in COVID-19 multiorgan impact Covid-19 and the cardiovascular system: a comprehensive review Distinct etiologies of highsensitivity troponin T elevation predict different mortality risks for patients hospitalized with COVID-19 Electrocardiographic manifestations of COVID-19 COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up High-sensitivity cardiac troponin can be an ally in the fight against COVID-19 Evolution of right and left ventricle routine and speckle-tracking echocardiography in patients recovering from coronavirus disease 2019: a longitudinal study Prognostic significance of tissue Doppler imaging-derived myocardial performance index in pediatric patients with dilated cardiomyopathy Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy Echocardiography for patients with COVID-19 in intensive care COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus Myocardial Damage by SARS-CoV-2: emerging mechanisms and therapies Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) Subclinical myocardial dysfunction in patients recovered from COVID-19 Echocardiographic characteristics and outcome in patients with COVID-19 infection and underlying cardiovascular disease Right ventricular dysfunction in critically ill COVID-19 ARDS Cardiac performance in patients hospitalized with COVID-19: a 6 month follow-up study Left ventricular myocardial performance index and its relationship with presystolic wave in prediabetic patients Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging Evaluation of biventricular function in patients with COVID-19 using speckle tracking echocardiography Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: a systematic review and meta-analysis The prognostic importance of TAPSE in early and in stable cardiovascular diseases Myocardial performance index increases at long-term follow-up in patients with mild to moderate COVID-19 Ebru Sahin MD https://orcid.org/0000-0002-2231-126XOnur Akgun MD https://orcid.org/0000-0003-0233-1084Rafig Gurbanov PhD https://orcid.org/0000-0002-5293-6447